
News and Publications
Publication Categories
New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors
7 Hills Pharma, in collaboration with MD Anderson and Texas Heart Institute, published a groundbreaking study in The Journal of Clinical Investigation showcasing how 7HP349 can convert "cold" melanoma tumors into "hot," T cell-enriched tumors, enhancing the efficacy of immune checkpoint blockade therapies. This novel approach offers a promising step forward in cancer immunotherapy.
7 Hills Pharma Announces First Healthy Volunteers Dosed In Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines
7 Hills Pharma announces the first healthy volunteers dosed in its Phase 1 trial of 7HP349, an immunostimulant aimed to enhance immuno-oncology drugs and COVID-19 & influenza vaccines, improving immune responses and increasing effectiveness in older adults.
7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies
7 Hills Pharma secures broad USPTO patent protection for its integrin activators, positioning the company as a key partner for immuno-oncology and COVID-19 vaccine developers. FDA-approved IND trials set to begin soon.
7 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines
7 Hills Pharma announces positive preclinical data on 7HP349, an oral immunostimulant that enhances COVID-19 vaccine effectiveness by boosting IgG antibody responses and accelerating immune protection. Learn how this integrin activator could improve vaccine efficacy, particularly for older adults.
7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
7 Hills Pharma launches a COVID-19 vaccine program targeting at-risk elderly, leveraging integrin activator technology to enhance immune responses and improve vaccine effectiveness. Learn more about this breakthrough approach.
7 Hills Pharma Appoints Lionel D. Lewis as Chief Medical Officer
7 Hills Pharma appoints Dr. Lionel D. Lewis as Chief Medical Officer, bringing extensive immuno-oncology expertise to advance 7HP349 integrin activator for solid tumor treatment. Learn more about this leadership addition.
7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
7 Hills Pharma forms a Scientific Advisory Board with top immuno-oncology experts to advance its integrin activator program, aiming to enhance checkpoint inhibitors and improve cancer immunotherapy effectiveness.
7 Hills Pharma Launches With $2 Million SBIR Grant in addition to $4 Million in Seed Capital to Pursue Novel Cancer Therapeutics to Promote a Productive Immune Response and Overcome Drug Resistance
7 Hills Pharma secures a $2M SBIR grant from the NIH, alongside $4M in seed funding, to develop integrin activators that enhance cancer immunotherapy and improve checkpoint inhibitor effectiveness in treating solid tumors.